.Pharmacolibrary.Drugs.S_SensoryOrgans.S01X_OtherOphthalmologicals.S01XA23_Sirolimus.Sirolimus

Information

Sirolimus, also known as rapamycin, is a macrolide immunosuppressant drug primarily used to prevent organ transplant rejection, particularly in kidney transplant recipients. It works by inhibiting the mammalian target of rapamycin (mTOR), leading to suppression of T-cell proliferation and activity. Approved by regulatory agencies including the FDA and EMA, sirolimus is also investigated for other immunosuppressive and antiproliferative indications.

Pharmacokinetics

Reported pharmacokinetics of oral sirolimus in adult renal transplant patients (n=31, mixed sex, mostly stable, with ongoing immunosuppressive co-medication). Population pharmacokinetic analysis; median values cited.

References

1. Zhang, Y, et al., & Li, X (2021). Population pharmacokinetics of sirolimus in Chinese adult liver transplant recipients: a retrospective study. Xenobiotica; the fate of foreign compounds in biological systems 51(12) 1408–1415. DOI:10.1080/00498254.2022.2025628 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34983304

2. Wang, D, et al., & Li, Z (2019). Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study. Oncology letters 18(3) 2412–2419. DOI:10.3892/ol.2019.10562 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31452734

3. Li, S, et al., & Wang, Y (2022). Population Pharmacokinetic Analysis and Dosing Optimization of Sirolimus in Children With Tuberous Sclerosis Complex. Journal of clinical pharmacology 62(8) 948–959. DOI:10.1002/jcph.2033 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35094415

Revisions

• 06/2025 initial generated model